3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
799
Precursor Cell Lymphoblastic Leukemia-Lymphoma
169
Recurrence
140
Neoplasms, Plasma Cell
110
Lymphoma
93
Leukemia
91
Neoplasms
81
Burkitt Lymphoma
57
Vomiting
51
Lymphoma, Non-Hodgkin
50
Immunoglobulin Light-chain Amyloidosis
49
Lymphoma, Large B-Cell, Diffuse
44
Nausea
38
Lymphoma, Mantle-Cell
38
Prostatic Neoplasms
31
Lymphoma, Follicular
30
Hodgkin Disease
29
Waldenstrom Macroglobulinemia
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
27
Neoplasm Metastasis
26
Leukemia, Lymphocytic, Chronic, B-Cell
26
Carcinoma, Non-Small-Cell Lung
26
Leukemia, Myeloid, Acute
25
Breast Neoplasms
25
Lung Neoplasms
22
Amyloidosis
21
Leukemia, Biphenotypic, Acute
18
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Extranodal NK-T-Cell
16
Smoldering Multiple Myeloma
15
Interventions
Operative Blood Salvage
1
Mastectomy, Modified Radical
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Systemic Inflammatory Response Syndrome
×
Dexamethasone
×
Clear all
NCT03125941
2019-12-02
DEX-MAS
Rigshospitalet, Denmark
Phase 4
Completed
130 enrolled
20 charts